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Background: Mexican Americans are at an increased risk of both thyroid dysfunction and metabolic syndrome
(MS). Thus it is conceivable that some components of the MS may be associated with the risk of thyroid
dysfunction in these individuals. Our objective was to investigate and replicate the potential association of MS traits
with thyroid dysfunction in Mexican Americans.
Methods: We conducted association testing for 18 MS traits in two large studies on Mexican Americans – the San
Antonio Family Heart Study (SAFHS) and the National Health and Nutrition Examination Survey (NHANES) 2007–10.
A total of 907 participants from 42 families in SAFHS and 1633 unrelated participants from NHANES 2007–10 were
included in this study. The outcome measures were prevalence of clinical and subclinical hypothyroidism and
thyroid function index (TFI) – a measure of thyroid function. For the SAFHS, we used polygenic regression analyses
with multiple covariates to test associations in setting of family studies. For the NHANES 2007–10, we corrected for
the survey design variables as needed for association analyses in survey data. In both datasets, we corrected for
age, sex and their linear and quadratic interactions.
Results: TFI was an accurate indicator of clinical thyroid status (area under the receiver-operating-characteristic
curve to detect clinical hypothyroidism, 0.98) in both SAFHS and NHANES 2007–10. Of the 18 MS traits, waist
circumference (WC) showed the most consistent association with TFI in both studies independently of age, sex and
body mass index (BMI). In the SAFHS and NHANES 2007–10 datasets, each standard deviation increase in WC was
associated with 0.13 (p < 0.001) and 0.11 (p < 0.001) unit increase in the TFI, respectively. In a series of polygenic
and linear regression models, central obesity (defined as WC≥ 102 cm in men and ≥88 cm in women) was
associated with clinical and subclinical hypothyroidism independent of age, sex, BMI and type 2 diabetes in both
datasets. Estimated prevalence of hypothyroidism was consistently high in those with central obesity, especially
below 45y of age.
Conclusions: WC independently associates with increased risk of thyroid dysfunction. Use of WC to identify
Mexican American subjects at high risk of thyroid dysfunction should be investigated in future studies.
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Reportedly 5-10% of the United States population has
subclinical or clinical hypothyroidism [1,2]. It is of
clinical interest that differential prevalence estimates
of hypothyroidism are influenced by age [3], sex , eth-
nicity [4] and other risk factors like presence of type 2
diabetes (T2D) [5,6]. Further, Mexican American and
white ethnicity is associated with a high risk of thyroid
dysfunction [3,7-9]. Knowledge of these risk factors is
crucial to identify hypothyroidism in its nascent, sub-
clinical stage since it is associated with preventable but
dangerous complications like hyperlipidemia, insulin
resistance, atherosclerosis and additional risks to mothers
and infants [10]. The accuracy of traditional strategies
to detect thyroid dysfunction that use a constellation of
symptoms and signs has been greatly increased by re-
cent improvements in the assays for thyroxine and thy-
roid stimulating hormone (TSH). For example, Helfand
and Crapo [10] have described that the sensitivity and
specificity of TSH to confirm thyroid disease is 98% and
92%, respectively. In primary care settings however, the
observed accuracy is not as high. For example, the
positive predictive value of a low TSH to detect hyper-
thyroidism has been reported to be only 24% while that
of a high TSH to detect hypothyroidism is only 6%
[10]. Improved screening programs for thyroid dys-
function will therefore need detection of differential
thyroid dysfunction risks across epidemiologically di-
verse groups.
There is now burgeoning evidence that vindicates a po-
tential link between thyroid dysfunction and metabolic
syndrome (MS). Even in a euthyroid state, a high normal
TSH is strongly associated with MS [11]. Similarly, in
the National Health and Nutrition Examination Survey
(NHANES) 2007–2008 data [4], body mass index (BMI)
and waist circumference (WC) were associated with
serum TSH levels. More recently, the Health, Ageing
and Body Composition Study [12] reported that unit in-
crease in TSH was associated with a 3% increase in the
odds of MS. It is also instructive in this regard that mu-
tations in the thyroid hormone receptor beta (THRB)
gene are associated with increased energy intake, hyper-
phagia and resting energy expenditure [13]. It is note-
worthy, however, that MS represents a constellation of
correlated phenotypic traits that together capture a wide
spectrum of metabolic disorders including prediabetes,
type 2 diabetes, insulin resistance, hypertension, obesity
and dyslipidemia [14]. However, the relative and compara-
tive contribution of these individual components of MS to
thyroid dysfunction is currently unknown.
Since Mexican Americans are at an increased risk of
MS, here we investigated the associations of MS-related
traits with indicators of thyroid dysfunction in Mexican
Americans from two large studies – San Antonio FamilyHeart Study (SAFHS) [15,16] and NHANES 2007–10.
The former study is uniquely suited to investigate the
hypothesized association between MS and thyroid func-
tion in families who are at a high risk of both MS and
thyroid abnormalities while the latter study provides a
rich, nationally representative population based setting.
We aimed to investigate and replicate the MS-thyroid
function nexus in these epidemiologically distinct scenar-
ios using an appropriate and robust analytical approach.
Here we report our finding that central obesity – a com-
ponent of MS – is additively, independently and signifi-
cantly associated with altered thyroid function.
Methods
Study participants
San Antonio Family Heart Study (SAFHS)
The recruitment and ascertainment procedures used in
the SAFHS have been described in details elsewhere
[15-17]. Briefly, the study has now recruited over 1600
subjects from 42 large and extended families with a ma-
jority of these subjects having completed up to three
additional follow-up visits spaced ~5 years apart. In the
analyses presented here we used the data and samples
collected during the first visit. Profiling of thyroid-related
traits was available for 919 subjects (from 42 families). In-
formed consent was obtained from all participants before
collection of samples. The Institutional Review Board of
the University of Texas Health Sciences Center at San
Antonio approved the study.
The National Health and Nutrition Examination Survey
(NHANES) 2007–10
NHANES is a yearly survey conducted by the National
Center of Health Statistics of the Centers for Disease
Control and Prevention (CDC). These datasets are
publicly available in a de-identified fashion. Detailed
description of the NHANES 2007–10 survey and sam-
pling strategies can be found online at http://www.cdc.
gov/nchs/nhanes.htm. The NHANES 2007–10 dataset
contained thyroid related components. From this
multi-ethnic dataset, we selected Mexican American
responders (n = 1636). Detailed characteristics of the
SAFHS and NHANES 2007–10 participants are shown
in Table 1.
Phenotypic traits related to thyroid function
Traits in SAFHS and NHANES 2007–10
In the SAFHS, available thyroid-related traits were total
and free thyroxine (TT4 and FT4), total and free tri-
iodothyronine (TT3 and FT3), reverse triiodothyronine
(RT3C), thyroxine binding globulin (TBG), thyroglobu-
lin (THG) and thyroid stimulating hormone (TSH).
R3TC was available for only 451 (49.1%) subjects. The
experimental methods used for measuring thyroid-related
Table 1 Characteristics of the study subjects
Characteristic SAFHS (n = 919) NHANES 2007–10 (n = 1636)
Value N Value N
Demographics
Age [mean (SE)] y 38.92 (0.54) 907 35.42 (0.81†) 1636
Females [n (%)] 555 (61.19) 907 842 (47.98††) 1636
Diabetes at enrolment [n (%)] 126 (13.91) 906 170 (7.35) 1635
Anthropometric indexes [mean (SE)]
Waist cm 94.71 (0.58) 898 95.65 (0.68) 1589
BMI Kg/m2 29.50 (0.23) 900 28.49 (0.27) 1618
WHR 0.89 (0.003) 897 - -
Blood pressure [mean (SE)]
Systolic mmHg 119.96 (0.61) 899 116.98 (0.75) 1504
Diastolic mmHg 70.56 (0.34) 899 66.84 (0.56) 1504
Biochemical indexes [mean (SE)]
Fasting glucose mmol/L 5.59 (0.07) 907 6.00 (0.11) 805
Fasting insulin μU/mL 16.72 (0.65) 894 15.64 (0.63) 803
Total serum cholesterol mg/dl 189.06 (1.32) 906 190.35 (1.54) 1636
Serum triglycerides mg/dl 151.56 (4.40) 906 141.15 (3.31) 805
HDL cholesterol mg/dl 50.54 (0.43) 905 48.90 (0.31) 1636
LDL cholesterol mg/dl 109.92 (1.10) 906 112.42 (1.52) 785
Thyroid related traits [mean (SE)]
Total thyroxine μg/dl 7.63 (0.07) 839 8.19 (0.08) 1628
Free thyroxine ng/dl 1.38 (0.01) 907 0.80 (0.01) 1636
Total triiodothyronine ng/dl 122.15 (0.92) 845 122.89 (1.03) 1635
Free triiodothyronine pg/ml 3.62 (0.04) 907 3.42 (0.03) 1634
Reverse triiodothyronine ng/dl 23.00 (0.30) 451 - -
Thyroxine binding globulin μg/ml 19.84 (0.19) 856 - -
Thyroglobulin ng/ml 11.56 (1.11) 879 11.27 (1.15) 1635
Thyroid stimulating hormone μU/ml 2.96 (0.14) 907 2.00 (0.14) 1635
†All proportions in NHANES samples are adjusted for survey design variables.
††For NHANES samples standard errors represent linearized standard errors.
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Of these traits, data on R3TC and TBG was not available
in the NHANES 2007–10 dataset. Thyroid profile data
for both studies is shown in Table 1. Finally, to capture
the information content of TSH, FT3 and FT4 in a sin-
gle, composite and continuous measure we developed
an index [which we termed the thyroid function index
(TFI)] as: TFI = TSH/(FT3 × FT4). We conceptualized
this index on the basis of the clinical expectation that
high values of TSH combined with low values of FT3
and FT4 values would be indicative of hypothyroidism
and, conversely, low value of TSH combined with high
values of FT3 and FT4 would be indicative of hyperthy-
roidism. Before conducting any association analyses for
the TFI trait, we first validated this index in both
SAFHS and NHANES 2007–10 participants.Clinical thyroid status
Based on the values of TSH, FT4 and FT3, we used the
recommended definitions [19,20] of thyroid status as
follows: clinical hypothyroidism (CO) – TSH ≥3.0 μIU/
ml AND (FT3 < 3.5 pmol/L OR FT4 < 10 pmol/L); sub-
clinical hypothyroidism (SO) – TSH ≥3.0 μIU/ml AND
(FT3 ≥ 3.5 pmol/L OR FT4 ≥ 10 pmol/L); clinical hyperthy-
roidism (CR) – TSH <0.3 μIU/ml AND (FT3 ≥ 6.5 pmol/L
OR FT4 ≥ 19 pmol/L); subclinical hyperthyroidism
(SR) – TSH <0.3 μIU/ml AND (FT3 < 6.5 pmol/L OR
FT4 < 19 pmol/L). Further, we defined hypothyroidism
as presence of clinical or subclinical hypothyroidism.
Metabolic syndrome related traits
We used data on 18 phenotypic traits related to meta-
bolic syndrome (12 continuous and six dichotomous).
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load plasma levels of glucose and insulin (measured by
2-hour oral glucose tolerance test); two homeostasis
model of assessment (HOMA) measures – HOMA-IR
representing insulin resistance and HOMA-β represent-
ing β-cell function; three measures of obesity – body
mass index (BMI), WC and waist-hip ratio (WHR); sys-
tolic and diastolic blood pressure; and three serum lipid
measures – total cholesterol, triglycerides and high-
density lipoprotein cholesterol (HDL-C). The methods
of assessment for these traits in the SAFHS and NHANES
2007–10 participants have been extensively described.
([16,17,21] and http://wwwn.cdc.gov/nchs/nhanes/search/
nhanes07_08.aspx/analyticnote_2007-2010.pdf. The defini-
tions of the six dichotomous traits (central obesity, raised
triglycerides, low HDL-C, T2D, high blood pressure and
metabolic syndrome) are provided in Additional file 1:
Table S1.
Statistical analyses
Inverse normalization of continuous traits
To ensure that i) inferences regarding association were
not influenced by a potentially non-normal distribution
of the continuous traits and ii) the results from the
SAFHS and NHANES 2007–10 can be evaluated using a
comparative metric, we inverse-normalized all continu-
ous traits before conducting regression analyses. This
transformation was used to generate inverse-normalized
traits having a mean of 0 and a standard deviation of 1
which was then used in the regression analyses.
Validation of TFI
We validated the TFI using receiver operating charac-
teristic (ROC) curves and estimating the comparative
area under the ROC curve (AUC) for the individual
components of TFI and TFI per se. To estimate AUC,
we used the Wilcoxon statistic and its standard error as
described by Hanley and McNeil [22]. We used the
STATA 12.0 package and roctab program to estimate
these statistics.
Polygenic regression analyses in SAFHS
We examined association between TFI and phenotypic
traits related to MS in the SAFHS participants using
polygenic regression models in a variance-components
framework [23,24]. These models implicitly account for
the genetic correlations and kinship structures and do
not consider the individual subjects as an independent
unit. The polygenic regression models were of the fol-
lowing form: TFIi =m + ∑ bkaik + gi + ei where, TFI is the
inverse-normalized log-transformed thyroid function
index; m is the trait mean; a is the covariate vector of di-
mension k with b as the corresponding regression coeffi-
cients; g is the polygenic effect and e is the residualerror for an individual indexed by i. The term g was
modeled as random effects based on the coefficients of
relationship in the kinship matrix. All models were first
run with only the MS-related trait as the covariate (un-
adjusted models) and then additionally included ad-
justments for age, age2, sex, age x sex and age2 x sex
interactions as covariates (adjusted models). Further,
we adjusted these models for the use of lipid lowering,
antihypertensive and antidiabetic agents. Statistical signifi-
cance of the association between a MS-related trait and
TFI was tested by constraining the corresponding regres-
sion coefficient to zero and comparing the log-likelihoods
of the constrained and unconstrained models in a likeli-
hood ratio χ2 test. These analyses were conducted using
the SOLAR software package [25]. Statistical significance
was tested at a global type I error rate of 0.05.
Survey design-corrected regression analyses in NHANES
2007–10 dataset
Since the NHANES dataset is based on a complex sam-
pling strategy to recruit a nationally representative sample,
we used appropriate survey based analytical methods as
detailed on the Centers for Disease Control and Preven-
tion website (http://www.cdc.gov/nchs/tutorials/nhanes/).
Briefly, we corrected for the proportional sampling units
and the sampling weights using the svyset command in
STATA 12.0 (Stata Corp, College Station, TX) software
package. Since it was likely that the subset of Mexican
Americans included in this study could have come from
some specific sampling units, we used the singleunit
(scaled) option in the svyset command. All regression
analyses were then conducted using the svy command
and regress subcommand.
Correction for multiple testing
We used 18 MS traits that are conceptually correlated
with each other to varying degrees. Therefore, these
traits do not represent independent tests. To estimate
the effective number of independent tests we used the
method of Li and Ji [26] which relies upon the eigen-
values of the full correlation matrix for the traits and
then uses a Sidak type correction to estimate the cor-
rected type I error rate for a global alpha error of 0.05.
Using this method we estimated that the corrected alpha
for the SAFHS dataset was 0.0051 and for the NHANES
dataset it was 0.0073.
Prevalence of hypothyroidism
In the SAFHS participants, we used a liability thresh-
old model approach to determine the prevalence of
hypothyroidism within combinatorial classes determined
by age categories and presence or absence of central obes-
ity. The polygenic regression models used in this scenario
were specifically tailored for discrete traits and additively
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2007–10 participants, we estimated the proportion of
hypothyroidism within each class after correcting for
the survey design variables (sampling weights, propor-
tionality sampling units and strata) using the svy com-
mand in STATA software package.
Results
Study participants
Of the 919 SAFHS and 1636 NHANES 2007–10 partici-
pants who underwent thyroid profiling, we included 907
SAFHS and 1633 NHANES 2007–10 participants for
whom data on FT3, FT4 and TSH were available. We ob-
served (Table 1) that the SAFHS participants were slightly
older (~3 y), had a higher proportion of females (~12%)
and had a higher prevalence of diabetes (~2 times) as
compared to the NHANES 2007–10 responders. However,
the anthropometric indexes, blood pressure, oral glucose
tolerance test results and serum lipid profiles were similar
in both studies. With regard to the thyroid profile, the
mean FT4 and TSH levels were higher in SAFHS partici-
pants but other thyroid-related traits were comparable
across the two studies. Consequently, the prevalence of
clinical hypothyroidism was comparable across the two
studies but the prevalence of subclinical hypothyroidism
was higher in the SAFHS participants than the NHANES
responders (25.5% vs 6.7%, Figure 1A). For the SAFHS, in-
formed consent was obtained from all participants before
data and sample collection. The study was approved by
the Institutional Review Board of the University of Texas
Health Science Center at San Antonio. The NHANES
study has been approved by the National Center of Health
Statistics Institutional Review Board under protocols #98-
12 and #2005-06. The study involved interviews, collection
of biological samples after taking informed consent from
all participants. All protocols used in the study are in
accordance with the Declaration of Helsinki.
Validation of thyroid function index
The distribution of TFI was heavily skewed in both studies
(Figure 1B, left panels). Therefore, we log-transformed the
TFI and found that the log-transformed TFI was distrib-
uted symmetrically in both datasets (Figure 1B, right
panels). However, we observed that the log-transformed
TFI had a non-significant skew in the SAFHS dataset
(p = 0.168) but not in the NHANES 2007–10 dataset
(p < 0.001). Therefore, in all ensuing analyses we further
corrected for this departure from normality by using an
inverse-normalization method. From this point forward,
TFI implies inverse-normalized, log-transformed TFI.
The TFI demonstrated (Figure 1C) a clear gradient of
distribution with very low values corroborating clinical
hyperthyroidism and high values characterizing clinical
hypothyroidism. In a head to head comparative evaluationof TFI and its individual components to diagnose clinical
hypothyroidism (Figure 1D), we observed that the TFI su-
perseded all of its individual components in both studies.
Specifically, the AUC for TFI was 98% while the AUCs for
TSH, FT3 and FT4 were consistently below that of TFI
in both the studies. These results therefore validated the
potential use of TFI as a replicable and generalizable
continuous measure of thyroid function.
MS-related traits and TFI: SAFHS participants
We studied the association of 18 MS-related traits with
TFI in SAFHS participants after accounting for the
kinship structure using a series of polygenic regression
models (Table 2). Even after accounting for age, sex
and their interactions in addition to the kinship structure,
we found that WC (β = 0.13, p = 0.0002), BMI (β = 0.11,
p = 0.0015), WHR (β = 0.09, p = 0.0103) and serum tri-
glycerides (β = 0.08, p = 0.0183) were significantly asso-
ciated with TFI. Consequently, central obesity (defined
on the basis of WC) and metabolic syndrome were also
significantly associated with TFI. In males, WHR (β = 0.20,
p = 0.008) and metabolic syndrome (β = 0.25, p = 0.0379)
were the only two traits significantly associated with
TFI. However, in females WC (β = 0.14, p = 0.001), BMI
(β = 0.13, p = 0.0026), WHR (β = 0.10, p = 0.022) and
central obesity (β = 0.20, p = 0.0247) achieved statistical
significance for association with TFI. Thus, these results
indicated a consistent association of central obesity with
TFI in the SAFHS participants.
MS-related traits and TFI: NHANES 2007–10
We conducted conceptually similar analyses in the
NHANES 2007–10 participants. Here we used the ap-
propriate survey design correction methods to statisti-
cally account for the potential confounding due to study
design. We observed (Table 3) that after correcting for
age, sex and their interactions, HOMA-IR (β = 0.06, p =
0.0448), WC (β = 0.11, p = 0.0008), BMI (β = 0.12, p =
0.0004), total serum cholesterol (β = 0.11, p = 0.0014)
and serum triglycerides (β = 0.09, p = 0.036) were statis-
tically significantly associated with TFI. In males, several
traits were significantly associated with TFI but the stron-
gest associations were again observed for WC (β = 0.20,
p = 7.6 × 10−8), BMI (β = 0.20, p = 1.3 × 10−7) and central
obesity (β = 0.30, p = 5.0 × 10−5). However, in females only
total serum cholesterol (β = 0.11, p = 0.0437) was statisti-
cally significantly associated.
Association of WC with TFI is independent of BMI
Since both WC and BMI were positively associated with
TFI in both studies, we compared the strength of associ-
ation of these two traits with TFI using interactive models
(Additional file 1: Table S2). Our results indicated that in
both the studies WC was significantly associated with TFI
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Figure 1 Development and validation of thyroid function index (TFI) as a marker of thyroid function. Results are color coded as blue for
SAFHS and red for NHANES 2007–10 participants. (A) Spectrum of clinical thyroid status. Bars represent prevalence (%) while error bars represent
95% confidence interval. CO, clinical hypothyroidism; SO, subclinical hypothyroidism; EU, euthyroid; SR, subclinical hyperthyroidism; CR, clinical
hyperthyroidism. (B) Effect of log-transformation on distribution of TFI. Left and right panels show histograms for raw and log-transformed TFI,
respectively. (C) Box and whisker plots showing distribution of log-normalized TFI by thyroid status. (D) Receiver operating characteristics (ROC)
curves comparing the discriminatory performance of TFI, TSH, FT3 and FT4 to detect clinical hypothyroidism. AUC, area under the ROC curve; CI,
confidence interval.
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in SAFHS and β = 0.28, p = 0.004 in NHANES 2007–10)
and females (β = 0.19, p = 0.018 in SAFHS and β = 0.19,
p = 0.07 in NHANES 2007–10) or in all participants to-
gether (β = 0.22, p = 0.001 in SAFHS and β = 0.13, p =
0.066 in NHANES 2007–10). Interestingly, a stronger
association signal between WC and TFI was observed
in males as compared to females in both SAFHS and
NAHNES 2007–10 participants in interactive models.
These results together indicated that the association of
WC with TFI is independent of the potential confounding
due to BMI.
Since it is clinically more appealing to use cutoffs of
WC and BMI, we used the similar approach to test
whether central obesity (defined on the basis of WC) is
associated with TFI independent of general obesity (de-
fined as BMI ≥ 30 kg/m2). The results of these analyses
are shown in Additional file 1: Table S3 and corroborate
the inferences drawn from results in Additional file 1:
Table S2. Therefore, to facilitate clinical use we evalu-
ated central obesity (instead of WC) as an independent
determinant of thyroid dysfunction in the succeeding
analyses.Central obesity associates with TFI independently of age
Since central obesity and thyroid dysfunction are both
associated with age, we next investigated whether the
association of central obesity with TFI is independent
of age. For this, we slid the age cutoff over the range
30-60 y and at each cutoff ran a polygenic regression
model that included dichotomized age and central
obesity as covariates and TFI as the dependent variable.
We observed that in SAFHS as well as NHANES 2007–
10 participants, the estimated regression coefficient for
central obesity (green diamonds and bars in Figure 2A
and 2B) was robustly stable and hovered between 0.2
and 0.3 irrespective of the cutoff for age. Further, as exist-
ing T2D is sometimes considered an indication for screen-
ing of thyroid dysfunction, we adjusted these models for
presence of T2D also. We observed (Figure 2C and 2D)
that the significant and independent association of central
obesity with TFI was sustained even after accounting for
age and presence of T2D.Prevalence of hypothyroidism based on central obesity
and age
Lastly, we estimated prevalence of clinical and subclin-
ical hypothyroidism in subgroups defined by 5-yearly
age intervals and presence or absence of central obesity.
In SAFHS participants (Figure 3A), prevalence of
hypothyroidism was higher within each age subgroup
in those with central obesity than without. In the
NHANES 2007–10 participants (Figure 3B), this find-
ing was replicated in all age categories except 45–49
and 55-59 y. Thus, central obesity showed an additive
and independent screening benefit especially below the
age of 45 y.Discussion
Our results demonstrate that WC, as a measure of cen-
tral obesity, is a significant and independent indicator
of thyroid dysfunction in Mexican Americans. These
results are substantiated by the fact that the associative
patterns were consistently observed in two large and
disparate studies on the same ethnic population. Inter-
estingly, the prevalence of clinical and subclinical
hypothyroidism was higher in the SAFHS than that in
the NHANES 2007–10 participants. This finding is im-
portant because subjects with subclinical hypothyroidism
are at a higher risk of eventual overt hypothyroidism in fu-
ture as compared to the euthyroid subjects [27] and our
results imply that such subjects may be concentrated
within families. Our findings therefore indicate that
central obesity may be not only an important player in
the multifactorial web of thyroid dysfunction but may
also contribute to the development of future clinical
hypothyroidism by predicting the subjects who are cur-
rently at a high risk of subclinical hypothyroidism.
The prevalence of subclinical and clinical hypothyroidism
estimated in this study may be somewhat higher than its
true population value for two reasons. First, there is
substantial evidence in the literature supporting the
view that TSH values may be increased in obesity and
morbid obesity [28-31]. Second, the TSH cutoff used to
define hypothyroidism here is restrictive. It is not un-
common to use 5 μU/ml as the upper limit of normal
TSH [19,32,33]. If this high cutoff value is used then
Table 3 Association of metabolic syndrome related traits with thyroid function index in NHANES 2007–2010
participants*
Metabolic syndrome-
related trait
All subjects Males Females
Unadjusted Adjusted† Unadjusted Adjusted†† Unadjusted Adjusted††
β p β P β p β p β P β P
Fasting glucose 0.09 0.08 0.01 0.78 0.15 <0.01 0.12 0.03 0.08 0.25 −0.02 0.76
Fasting insulin 0.05 0.13 0.06 0.07 0.12 <0.01 0.12 <0.01 −0.05 0.32 −0.03 0.56
HOMA-IR 0.07 0.02 0.06 0.04 0.15 <0.001 0.14 <0.001 −0.02 0.70 −0.03 0.52
HOMA-β 0.00 0.98 0.05 0.20 0.05 0.30 0.08 0.12 −0.09 0.16 0.00 0.98
WC 0.16 <0.0001 0.11 <0.001 0.21 <0.0001 0.20 <0.0001 0.13 <0.001 0.06 0.17
BMI 0.15 <0.0001 0.12 <0.001 0.20 <0.0001 0.20 <0.0001 0.11 <0.01 0.03 0.40
Total serum cholesterol 0.16 <0.0001 0.11 <0.01 0.13 <0.001 0.13 <0.001 0.20 <0.001 0.11 0.04
Serum triglycerides 0.13 <0.001 0.09 0.04 0.11 <0.01 0.10 0.02 0.20 0.001 0.12 0.07
Serum HDL cholesterol 0.00 0.98 0.00 0.85 −0.10 <0.001 −0.10 <0.001 0.05 0.09 0.04 0.11
Central obesity 0.32 <0.0001 0.22 <0.001 0.36 <0.0001 0.30 <0.0001 0.22 <0.01 0.05 0.58
Raised triglycerides 0.17 <0.01 0.01 0.90 0.09 0.17 −0.01 0.88 0.31 <0.01 0.13 0.20
Low HDL cholesterol 0.10 <0.01 0.04 0.12 0.14 0.02 0.10 0.08 0.02 0.69 −0.03 0.52
High blood pressure 0.31 <0.0001 0.08 0.16 0.32 <0.01 0.17 0.13 0.34 <0.001 0.02 0.83
Type 2 diabetes 0.30 <0.0001 0.04 0.55 0.24 0.02 0.00 0.98 0.33 0.001 0.07 0.47
Metabolic syndrome 0.32 <0.0001 0.16 0.05 0.29 0.01 0.19 0.11 0.29 0.06 0.09 0.62
*In this set, data on 2-hour glucose, 2-hour insulin and WHR were not available; †, adjusted for age, age2, sex, age x sex interaction and age2 x sex interaction;
††, adjusted for age and age2; numbers in bold face indicate statistically significant associations after correcting for multiple testing.
Table 2 Association of metabolic syndrome related traits with thyroid function index in the SAFHS participants
Metabolic syndrome-related trait All subjects Males Females
Unadjusted Adjusted† Unadjusted Adjusted†† Unadjusted Adjusted††
β p β p β p β p β P β p
Fasting glucose 0.08 0.03 −0.02 0.62 0.07 0.19 0.01 0.91 0.07 0.14 −0.03 0.53
2-hour glucose 0.14 <0.0001 0.05 0.15 0.16 <0.01 0.11 0.05 0.09 0.06 −0.01 0.82
Fasting insulin 0.04 0.27 0.00 0.96 0.03 0.62 0.01 0.78 0.03 0.52 −0.01 0.77
2-hour insulin 0.08 0.02 0.04 0.22 0.07 0.18 0.04 0.43 0.07 0.13 0.03 0.47
HOMA-IR 0.06 0.12 0.00 0.94 0.04 0.41 0.02 0.78 0.05 0.33 −0.02 0.68
HOMA-β −0.07 0.06 0.02 0.58 −0.05 0.38 0.01 0.86 −0.06 0.1763 0.04 0.47
WC 0.19 <0.0001 0.13 <0.001 0.12 0.04 0.08 0.18 0.20 <0.0001 0.14 0.001
BMI 0.15 <0.0001 0.11 <0.01 0.04 0.45 0.02 0.76 0.18 <0.0001 0.13 <0.01
WHR 0.15 <0.0001 0.09 0.01 0.23 <0.001 0.20 <0.01 0.16 0.0001 0.10 0.02
Total serum cholesterol 0.12 0.0001 0.06 0.06 0.08 0.10 0.07 0.19 0.11 0.0101 0.03 0.46
Serum triglycerides 0.15 <0.0001 0.08 0.02 0.12 0.02 0.09 0.07 0.14 <0.01 0.07 0.14
Serum HDL cholesterol 0.05 0.11 0.06 0.06 0.05 0.32 0.07 0.15 0.02 0.67 0.02 0.69
Central obesity 0.30 <0.0001 0.20 <0.01 0.16 0.14 0.13 0.26 0.33 0.0001 0.20 0.02
Raised triglycerides 0.16 0.02 0.05 0.42 0.13 0.19 0.09 0.39 0.19 0.03 0.06 0.49
Low HDL cholesterol −0.02 0.81 −0.05 0.46 0.12 0.28 0.08 0.49 −0.11 0.20 −0.11 0.17
High blood pressure −0.25 <0.01 −0.05 0.61 −0.10 0.44 0.06 0.65 −0.26 0.01 −0.06 0.61
Type 2 diabetes 0.15 0.04 −0.04 0.60 0.14 0.22 −0.01 0.95 0.15 0.14 −0.04 0.70
Metabolic syndrome 0.27 <0.0001 0.16 0.02 0.28 0.02 0.25 0.04 0.24 <0.01 0.11 0.24
†Adjusted for age, age2, sex, age x sex interaction and age2 x sex interaction; ††, adjusted for age and age2; numbers in bold face indicate statistically significant
associations after correcting for multiple testing.
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After adjusting for diabetes status
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After adjusting for diabetes status
Figure 2 Association of central obesity with TFI is independent of age. Results for SAFHS participants are shown on the blue background
on left while those for the NHANES 2007–10 participants are shown on pink background on right. (A-B) Estimated regression coefficients (β) for
age (purple circles) and central obesity (green diamonds) in a single polygenic model for each cutoff of age. In these analyses age was
dichotomized at the cutoffs shown on the abscissa and polygenic regression was run at each cutoff. Error bars represent 95% confidence
intervals around the regression coefficient. (C-D) Analyses similar to those in (A-B) but additionally accounting for presence of type 2 diabetes.
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http://www.biomedcentral.com/1472-6823/14/46expectedly the prevalence of hypothyroidism will be less
than that reported here. We chose to use the cutoff of
3 μU/ml for the following three reasons: i) The main
objective of this study was not to estimate prevalence of
hypothyroidism but rather to compare the prevalence
estimates across categories of predictor variables like
waist circumference; ii) The criteria used for diagnosis
of clinical thyroid states used in this study are based
on clinical practice guidelines recommended by the
American Association of Clinical Endocrinologists and
the American Thyroid Association [34] and therefore
follow the standards-of-care; and iii) Using these criteria,cross-ethnicity comparisons in American populations can
be undertaken in future even if we have not included other
ethnic groups in this study. In addition, we used TFI as a
surrogate measure of thyroid function. This novel measure
has the advantage that it combines the information
content of TSH, FT3 and FT4 in the identification of
hypothyroidism. However, we would like to point out
that the clinical use of TFI has thus far not been vali-
dated in other populations and should be considered
only illustrative rather than conclusive.
Biological plausibility in support of our findings is pro-
vided by a series of recent observations. First, thyroid
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Figure 3 Utility of central obesity as an additional screening measure to detect thyroid dysfunction. Results for SAFHS participants are
shown on the blue background in (A) while those for the NHANES 2007–10 participants are shown on pink background in (B). Each panel shows
color coded bars representing prevalence of the indicated clinical thyroid status within each age category. COb+, central obesity present; COb-,
central obesity absent.
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http://www.biomedcentral.com/1472-6823/14/46stimulating hormone receptors (TSHR) are present in tis-
sues other than the thyroid, especially in differentiating
adipocytes [35]. Whilst it is conceivable that increasing
TSHR concentration in obesity may attract additional re-
lease of TSH through a positive feedback to the pituitary,
direct data in this regard are currently unavailable. As
explained by Skudlinski et al. [36] and Mueller et al.
[37], however the interactions between TSH and TSHR
are very complex and therefore expectation of a simple
positive feedback loop conjectured here may be overly
simplistic. Second, thyroid hormone has been shown
[38] to regulate expression of the gene encoding apoli-
poprotein M by binding to a hormone response element
in the promoter of this gene. It is noteworthy that apoli-
poprotein M plays an important role in MS and obesity
[38-40]. Third, in the 3 T3-L1 adipocytes it was observed
[41] that in vitro treatment with triiodothyronine and
thyroxine increased the expression of the gene encoding
Plasminogen activator inhibitor 1, a key contributor in
the inflammatory and cardiovascular complications of
obesity. Fourth, triiodothyronine regulates the expres-
sion of the apolipoprotein AV gene, another importantcontributor to the complex pathogenesis of obesity and
its complications [42]. Considered in totality, these
studies lend biological credibility to our observation
that WC is associated with thyroid function although
the exact mechanism of this association remains
unknown.
Our results are conceptually in agreement with the
observed association of WC-based indices with altered
thyroid function in other populations like Chinese chil-
dren [43], Turkish women [44], other US ethnic groups
[4], Italian euthyroid subjects [45] and Korean adults
[46]. It is interesting that these studies have addressed
different aspects of metabolic syndrome but none of these
studies has directly and simultaneously assessed asso-
ciations of the components of MS with thyroid dys-
function. For example, the study by Kitahara et al. [4],
demonstrated that in a predominantly non-Hispanic
white population of US men and women, higher values of
BMI and WC were associated with increased TSH levels.
However, a direct comparison of WC and BMI was not
done in that study. Similarly, two studies [44,45] have spe-
cifically evaluated the association with a focus on insulin
Mamtani et al. BMC Endocrine Disorders 2014, 14:46 Page 11 of 13
http://www.biomedcentral.com/1472-6823/14/46sensitivity and resistance with thyroid dysfunction. The
study by Jung et al., used WHR as the index of central
obesity and found similar results as those of ours but they
did not include all the components included in this study.
As a consequence of these differences a direct comparison
of our results with other studies is not possible but all
these studies support the paradigm that obesity and
thyroid dysfunction are associated with each other.
Some limitations need to be considered before gener-
alizing these results. First, both SAFHS and NHANES
2007–10 studies did not permit a direct investigation of
a predictive value of future hypothyroidism – an import-
ant requirement before central obesity can be considered
as a marker of thyroid dysfunction. Also, it has been ar-
gued that hypothyroidism itself may lead to obesity [47].
The direction of causal pathways cannot be established
from this study. Second, we did not use the age-specific
diagnostic criteria for defining hypothyroidism that are
now in vogue [48]. However, since our results were ad-
justed for age, age2, sex and their interactions, we do not
anticipate that our results would be influenced by any la-
tent misclassification. Third, both SAFHS and NHANES
2007–10 datasets are, by design, cross-sectional in nature
and follow-up data on these subjects is not available. Our
reasoning that waist circumference might contribute to an
increased risk of clinical hypothyroidism by predicting
existing subclinical hypothyroidism is only a notional ar-
gument and can be affirmed only by longitudinal studies.
Fourth, the reasons for some differences observed between
males and females in the two SAFHS and NHANES
2007–10 datasets (for example, WC was significantly asso-
ciated with TFI in females in SAFHS but in males in
NHANES 2007–2010) are unclear and need to be investi-
gated in future studies. It is possible that these significance
values are primarily a result of the gender differential
across the two datasets (SAFHS had 61% females while
NHANES 2007–2010 had only 48% females). However,
other reasons of biological of epidemiological dispositions
cannot be overruled. Nevertheless, the fact that sex-
adjusted results showed significant association of WC
with TFI in both datasets demonstrates that the stratifi-
cation due to sex may be minimal. Fifth, in our study we
used the recommended [49] cutoffs for WC and BMI
however there is now a growing opinion that “metabol-
ically healthy obese” (MHO) subgroup [50] of MS is a
special group with subclinical obesity or an overweight
status that is associated with increased cardiovascular
risks. Our study cannot directly comment on this but
it is conceivable that this group may also be associated
with altered thyroid disease risks. Future studies need
to consider if central and general obesity are also asso-
ciated with MHO status and therefore are able to
identify individuals with increased likelihood of thy-
roid dysfunction.Lastly, for dichotomizing the WC values we used cutoffs
of ≥102 cm in men and ≥88 cm in women. While these
cutoffs have been previously used for all US populations
[49], lower cutoffs – especially those associated with in-
creased likelihood of cardiovascular diseases – may pro-
vide even more sensitive prediction of thyroid dysfunction
at the expense of specificity. The IDF recommends a cut-
off of ≥90 cm and ≥80 cm for men and women of Mexican
American and Hispanic origin [51]. As demonstrated by
Ford et al. [52], these differences in the cutoffs can signifi-
cantly influence the estimates of prevalence of abdominal
obesity. At this time it is unclear how these definitions
might impact the association of central obesity with
thyroid dysfunction. Therefore, additional studies are
required to investigate the potential effect of sliding
cutoffs on the association of dichotomized WC with
thyroid dysfunction.
Our study has an important indirect implication. Com-
bined with the results of previous studies our results raise
the possibility of considering central obesity as a screening
adjunct to detect thyroid dysfunction. Recommendations
for thyroid disease screening vary widely. The American
Thyroid Association recommends [53] beginning screen-
ing at 35 y with 5-yearly follow-ups. The American College
of Physicians recoomends screening in women over 50
who have at least one symptom suggestive of thyroid dis-
ease [54]. The American Academy of Family Physicians
recommends [55] screening for high risk populations but
the list of high-risk groups includes diabetes, autoimmune
disorders, women with a history of thyroid disease, preg-
nant women and women over 35 years. The American
Association of Clinical Endocrinologists recommends
screening before childbearing age or pregnancy or during
the first trimester [56]. Despite these varied recommenda-
tions the emerging common thread is that thyroid screen-
ing is likely to be beneficial in high-risk populations. In
this vein, our observations raise the possibility that screen-
ing for thyroid dysfunction in Mexican Americans based
on waist circumference, especially at younger ages, may
yield additional benefits. Future studies need to carefully
address this possibility.
Conclusions
In two disparate and large population based studies of
Mexican Americans, we found that WC is an inde-
pendent predictor of thyroid function. This association
is independent of age, gender and BMI. These results
implore that in high-risk, high-prevalence populations
like Mexican Americans, consideration needs to be
given to WC as a potential screening tool for thyroid
dysfunction Future studies need to evaluate the screen-
ing benefits, harms and costs associated with predic-
tion of incident thyroid dysfunction based on current
evidence of central obesity.
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